Navigation Links
Karolinska Development and Uminova Invest Sign Co-operation Agreement
Date:1/14/2010

STOCKHOLM and UMEA, Sweden, January 14 /PRNewswire/ -- Karolinska Development AB and Uminova Invest AB have entered into a co-operation agreement that will enrich the flow of investment opportunities available to Karolinska Development and enable cost effective commercial development for Uminova Invest's portfolio companies. The agreement involves evaluation of potential investments; advise to existing portfolio companies as well as exit issues.

Uminova Invest is a regional private equity capital firm providing capital and competence to prospective growth companies and entrepreneurs with a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

"Umea region excels having created a very strong cluster of life science innovations over the past years and this agreement offers us access to some very exciting commercial opportunities", says Conny Bogentoft, CEO of Karolinska Development.

"Over the past years we have had an ongoing exchange with Karolinska Development, this has now been formalized. This formal co-operation agreement provides further opportunities to create viable companies", says Jan Olsson, CEO of Uminova Invest.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com

About Uminova Invest

Uminova Invest focuses on prospective growth companies and people with interesting ideas and an entrepreneur spirit at a stage when the addition of capital and competence is vital for the company's growth. The idea, product or service must be unique with a high market potential, and must have a connection to the Umea University or other educational and research activities in the county of Vasterbotten. http://www.uminovainvest.se

    For more information, please contact:

    Conny Bogentoft CEO Karolinska Development
    Tel: +46(0)706-88-61-43, e-mail:
    conny.bogentoft@karolinskadevelopment.com

    Jan Olsson CEO Uminova Invest
    Tel: +46(0)703-44-16-80, email: jan.olsson@uminovainvest.se

SOURCE Karolinska Development AB and Uminova Invest AB


'/>"/>
SOURCE Karolinska Development AB and Uminova Invest AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
2. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
3. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
4. Karolinska Development Closes Fully Subscribed New Share Issue
5. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... 2017 , ... Any expert in stem cell research or stem cell medicine ... half a century. Despite their essential roles in human health and regenerative medicine, ... tags developed for this purpose also tag other, more abundant, non-stem tissue cells ( ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
(Date:8/11/2017)... ... 2017 , ... Algenist continues to disrupt the skincare industry with today’s debut ... , Collagen is the key structural element skin needs to maintain its youthful appearance ... First to market with proprietary collagen water active , ...
(Date:8/10/2017)... ... August 09, 2017 , ... Each year in the United States more ... to live an independent lifestyle and, even worse, the one-year mortality rate is high, ... at the University of California Davis Medical Center (Sacramento) and Second Xiangya Hospital of ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):